Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report

Clicks: 162
ID: 271639
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
RET-rearrangement occurs in 1 to 2% of patients with non-small cell lung cancer (NSCLC), typically among non-smokers, and it is associated with an increased incidence of brain metastasis. While selpercatinib and pralsetinib are active for RET-rearranged NSCLC, the optimal standard frontline regimen …
Reference Key
s2021cancerfrontline Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Baby S;Khalil F;Tanvetyanon T;;
Journal cancer treatment and research communications
Year 2021
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/34166867
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:34166867 doi:10.1016/j.ctarc.2021.100423 sheon baby farah khalil tawee tanvetyanon

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.